Your browser doesn't support javascript.
loading
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Lücking, Ulrich; Wortmann, Lars; Wengner, Antje M; Lefranc, Julien; Lienau, Philip; Briem, Hans; Siemeister, Gerhard; Bömer, Ulf; Denner, Karsten; Schäfer, Martina; Koppitz, Marcus; Eis, Knut; Bartels, Florian; Bader, Benjamin; Bone, Wilhelm; Moosmayer, Dieter; Holton, Simon J; Eberspächer, Uwe; Grudzinska-Goebel, Joanna; Schatz, Christoph; Deeg, Gesa; Mumberg, Dominik; von Nussbaum, Franz.
Afiliação
  • Lücking U; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Wortmann L; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Wengner AM; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Lefranc J; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Lienau P; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Briem H; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Siemeister G; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Bömer U; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Denner K; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Schäfer M; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Koppitz M; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Eis K; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Bartels F; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Bader B; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Bone W; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Moosmayer D; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Holton SJ; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Eberspächer U; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Grudzinska-Goebel J; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Schatz C; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Deeg G; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Mumberg D; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • von Nussbaum F; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
J Med Chem ; 63(13): 7293-7325, 2020 07 09.
Article em En | MEDLINE | ID: mdl-32502336
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Morfolinas / Proteínas Mutadas de Ataxia Telangiectasia / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Morfolinas / Proteínas Mutadas de Ataxia Telangiectasia / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos